Biotech Values

[ariadndndough]

CS on TGTX
TG Therapeutics (TGTX)
TGR-1202 is a delta specific inhibitor most similar to GILD's idelalisib. It is being developed in combination with TGTX's proprietary anti-CD20 antibody. Alone, these assets would be less interesting but because TGTX has global rights (excluding India) to drugs in two validated and combinable drug classes for NHL and CLL, TGTX is an attractive strategic acquisition target for a hem/onc company such as PCYC, CELG, or JNJ that have complementary programs (e.g. BTK inhibitors). The assessment of the risk of TGR-1202 to INFI will largely depend on whether TGTX is acquired or partners and who the acquirer/partner is